Terazosin Capsule
Product Images NDC 71335-3123

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 71335-3123). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Description (Figure 01)

Image Description (Figure 01)
This text provides information related to the mean change in total symptom score from baseline for two different treatments - placebo and terazosin. It also outlines the mean increase in peak flow rate in mL/sec from baseline for terazosin and placebo over a span of three months. The data appears to be part of a study or clinical trial.*
FDA Label Image

Image Description (Figure 02)

Image Description (Figure 02)
This is a summary of the mean change in the total symptom score from the baseline in a long-term, open-label, non-placebo controlled study involving 494 participants. The chart shows the mean change over a span of 30 months at different time points (0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30 months).*
FDA Label Image

Image Description (Figure 03)

Image Description (Figure 03)
This is a graph showing the mean change in peak flow rate from the baseline in a long-term, open-label, non-placebo controlled study involving 494 participants over a period of 30 months. The data is presented in mL/sec and is displayed for various time points ranging from 0 to 30 months.*
FDA Label Image

Label (Lbl713353123)

Label (Lbl713353123)
Each capsule contains Terazosin Hydrochloride equivalent to terazosin 10 mg. The usual dosage can be found in the package insert by scanning the QR code provided. It is recommended to store the capsules between 20° to 25°C (68° to 77°F) in a tight, light-resistant container to protect them from light and moisture. Manufactured by OrBion Pharmaceuticals, these capsules are for prescription use only.*
FDA Label Image

Image Description (Structure001)

Image Description (Structure001)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.